Plasma Cell Neoplasm Clinical Trials

8 recruitingLast updated: June 21, 2026

There are 8 actively recruiting plasma cell neoplasm clinical trials across 2 countries. Studies span Early Phase 1, Phase 1, Phase 2. Top locations include Chapel Hill, North Carolina, United States, Beijing, Beijing Municipality, China, Greenville, North Carolina, United States. Updated daily from ClinicalTrials.gov.


Plasma Cell Neoplasm Trials at a Glance

8 actively recruiting trials for plasma cell neoplasm are listed on ClinicalTrialsFinder across 6 cities in 2 countries. The largest study group is Early Phase 1 with 2 trials, with the heaviest enrollment activity in Chapel Hill, Beijing, and Greenville. Lead sponsors running plasma cell neoplasm studies include UNC Lineberger Comprehensive Cancer Center, M.D. Anderson Cancer Center, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd..

Browse plasma cell neoplasm trials by phase

Treatments under study

About Plasma Cell Neoplasm Clinical Trials

Looking for clinical trials for Plasma Cell Neoplasm? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Plasma Cell Neoplasm trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Plasma Cell Neoplasm clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 18 of 8 trials

Recruiting
Early Phase 1

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command20 enrolled1 locationNCT07519187
Recruiting
Phase 1

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma and Other Plasma Cell Neoplasms
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.15 enrolled5 locationsNCT07529782
Recruiting
Phase 2

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma

Multiple MyelomaPlasma Cell NeoplasmMalignant Plasma Cell Neoplasm
M.D. Anderson Cancer Center30 enrolled1 locationNCT05336383
Recruiting

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

LymphomaLeukemiaMyelodysplastic Syndromes+5 more
UNC Lineberger Comprehensive Cancer Center15,000 enrolled1 locationNCT01137643
Recruiting

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

LymphomaUnspecified Adult Solid Tumor, Protocol SpecificLeukemia+6 more
Barbara Ann Karmanos Cancer Institute1 locationNCT00935090
Recruiting

Registry of Older Patients With Cancer

LymphomaUnspecified Adult Solid Tumor, Protocol SpecificLeukemia+6 more
UNC Lineberger Comprehensive Cancer Center3,000 enrolled7 locationsNCT01137825
Recruiting
Early Phase 1

A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma

Multiple Myeloma and Malignant Plasma Cell Neoplasms
Peking University First Hospital50 enrolled2 locationsNCT06717113
Recruiting

Longitudinal Data Registry of Plasma Cell Dyscrasia

Multiple Myeloma and Other Plasma Cell Neoplasms
Shanghai Zhongshan Hospital2,000 enrolled1 locationNCT06760052